SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Sven Kili, ISCT 2022 Annual Meeting co-chair/Court
Business
At ISCT This Week, Cell & Gene Therapy Grows Up
BioSpace sat down with Sven Kili, 2022 ISCT Annual Meeting co-chair, to preview the event, which will focus on 4 key subject areas including launch and commercialization of cell and gene therapies.
May 3, 2022
 · 
5 min read
 · 
Heather McKenzie
Alnylam (Pavel Kapysh/Shutterstock)
Drug Development
Delays are the Name of the Game as Alnylam Gives Q1 Update
Alnylam announced another delay, this one caused by a much more sinister reason – the invasion of Ukraine, now heading into its third month and causing disruption on a multi-faceted and global scale.
April 28, 2022
 · 
3 min read
 · 
Heather McKenzie
BioMarin HQ/courtesy of BioMarin
Drug Development
BioMarin’s Record Q1 Driven by Recently Approved Achondroplasia Therapy
The Q1 results for Voxzogo gave BioMarin the confidence to raise its 2022 full-year guidance to between $100 million to $125 million (net product revenue) for the drug.
April 27, 2022
 · 
4 min read
 · 
Heather McKenzie
Frédéric Triebel (left) and Marc Voigt/Courtesy of
Drug Development
LAG-3 Pioneer Discusses BMS Milestone and Potential of the New Checkpoint
Triebel holds the distinction of having discovered LAG-3 in 1990. Today, the company he founded is leveraging the handy molecule against cancer and autoimmune disease.
April 25, 2022
 · 
6 min read
 · 
Heather McKenzie
External view of Boehringer Ingelheim's headquarters in Silicon Valley
Business
Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
April 6, 2022
 · 
3 min read
 · 
Heather McKenzie
Policy
BMS-Sponsored Diversity in Oncology Series Tackles Representation in Clinical Trials
BMS partnered with digital oncology company GRYT Health to convene a series of “courageous conversations” between patients, practitioners, caregivers, clinical trial teams and public health leaders.
April 5, 2022
 · 
7 min read
 · 
Heather McKenzie
From left: Amylyx Co-founders and Co-CEOs Justin K
Drug Development
Amylyx ALS Candidate Denied in Painfully Close AdCom Vote (Updated)
In a meeting of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, six members voted not to approve the NDA for Amylyx’s ALS candidate, AMX0035, while four voted in favor.
March 30, 2022
 · 
4 min read
 · 
Heather McKenzie
Civica is putting in efforts to make affordable in
Business
Civica is Rallying Leaders to Make Affordable Insulin by 2024
Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.
March 28, 2022
 · 
8 min read
 · 
Heather McKenzie
From left: Amylyx Co-founders and Co-CEOs Justin K
Drug Development
UPDATED: Amylyx - and Hopeful ALS Community – Face Another Moment of Truth
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since Aduhelm as it weighs the merits of Amylyx’s AMX0035 for ALS on Wednesday, March 30.
March 27, 2022
 · 
8 min read
 · 
Heather McKenzie
Omega Therapeutics team, Courtesy Omega Therapeuti
Business
Modulating Gene Expression to Stop Diseases in Their Tracks: a Pioneering Journey
Omega Therapeutics is harnessing the power of epigenetics in an unprecedented way and engineering programmable epigenetic mRNA therapeutics to transform medicine in the service of patients.
March 20, 2022
 · 
6 min read
 · 
Heather McKenzie
A Novartis building under a blue sky/courtesy of C
Drug Development
Novartis’ Fortuitous Discovery Could Deliver Breakthrough in Huntington’s Disease
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
March 19, 2022
 · 
4 min read
 · 
Heather McKenzie
Nitpicker/Shutterstock
Drug Development
BMS Celebrates A New Day in Cancer Treatment with Approval of Opdualag
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
March 19, 2022
 · 
3 min read
 · 
Heather McKenzie
Pavel Kapysh/Shutterstock
Drug Development
New NurOwn Data Backs Up Importance of UNC13A in ALS
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
March 16, 2022
 · 
3 min read
 · 
Heather McKenzie
Photos courtesy of Shoreline Biosciences, Axogen a
Life Sciences Industry Emphasizes Growth, Purpose in Fight for Talent
According to a recent BioSpace report, the top three motivators for employees to look for a new job are growth opportunities, greater compensation and the desire for a new challenge.
March 15, 2022
 · 
5 min read
 · 
Heather McKenzie
Business
Sanofi Unites Under a Single Purpose at Cambridge Crossing
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
March 11, 2022
 · 
5 min read
 · 
Heather McKenzie
Load More